Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers

Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA
Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers ( Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA )
7 May 2025

Metastasis-directed radiotherapy shows good prognosis for oligometastatic kidney cancer

Dr Chad Tang - MD Anderson Cancer Center, Houston, USA
Metastasis-directed radiotherapy shows good prognosis for oligometastatic kidney cancer ( Dr Chad Tang - MD Anderson Cancer Center, Houston, USA )
6 May 2025

Circulating tumour DNA can guide adjuvant immunotherapy for mismatch repair-deficient tumours

Dr Yelena Yuriy Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA
Circulating tumour DNA can guide adjuvant immunotherapy for mismatch repair-deficient tumours ( Dr Yelena Yuriy Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )
6 May 2025

Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results

Dr Aditya Shreenivas - CIty of Hope, Duarte, USA
Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results ( Dr Aditya Shreenivas - CIty of Hope, Duarte, USA )
6 May 2025

Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer

Dr Ravindra Uppaluri - Dana-Farber Brigham Cancer Center, Boston, USA
Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer ( Dr Ravindra Uppaluri - Dana-Farber Brigham Cancer Center, Boston, USA )
6 May 2025

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma

Dr Milad Ibrahim - NYU Langone Health, New York, USA
EGFR shows to be a promising therapeutic target in NF1 mutant melanoma ( Dr Milad Ibrahim - NYU Langone Health, New York, USA )
6 May 2025

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom
ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )
25 Apr 2025

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )
10 Apr 2025

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA
Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer ( Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA )
10 Apr 2025

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC

Dr Sacha Rothschild - University of Basel, Basel, Switzerland
Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC ( Dr Sacha Rothschild - University of Basel, Basel, Switzerland )
10 Apr 2025

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany
Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )
8 Apr 2025

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
8 Apr 2025